Safety and Efficacy of Protocol for Shortening the Duration of Dual Antiplatelet Therapy after Second and Third Generation Drug Eluting Stent Implantation in Patients Administered Oral Anticoagulant Agent

Safety and Efficacy of Protocol for Shortening the Duration of Dual Antiplatelet Therapy after Second and Third Generation Drug Eluting Stent Implantation in Patients Administered Oral Anticoagulant Agent - Safety and Efficacy of Protocol for Shortening the Duration of Dual Antiplatelet Therapy after Second and Third Generation Drug Eluting Stent Implantation in Patients Administered Oral Anticoagulant Agent

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017410

Enrollment

200

Registered

2015-05-07

Start date

2015-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Consecutive patients with coronary artery disease who were administered oral anticoagulant agent

Interventions

One month duration of aspirin after drug eluting implantation in patients who were administered oral anticoagulant therapy Conventional DAPT in patients who were not administered anticoagulant therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with coronary artery disease who were treated with second and third generation drug eluting stent 2. Patients with concomitant administration of oral anticoagulation agent 3. Patients over the age of 20 4. Patients who were obtained written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who could not tolerate antiplatelet therapy or anticoagulation therapy 2. Patients who appeared to be inappropriate for this study, determined by the investigators

Design outcomes

Primary

Measure	Time frame
Composite of major adverse events (death, acute coronary syndrome, stroke, any revascularization and systemic embolism), and hemorrhagic complication measured by BARC	—

Countries

Japan

Contacts

Public ContactKazunori Horie

Sendai Kousei Hospital Cardiovascular Division

horihori1015@gmail.com+81-22-222-6181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026